9.08
Schlusskurs vom Vortag:
$9.08
Offen:
$9.06
24-Stunden-Volumen:
1.47M
Relative Volume:
1.04
Marktkapitalisierung:
$437.72M
Einnahmen:
$91.06M
Nettoeinkommen (Verlust:
$-503.14M
KGV:
-1.0822
EPS:
-8.39
Netto-Cashflow:
$-424.74M
1W Leistung:
-1.84%
1M Leistung:
+37.16%
6M Leistung:
+57.09%
1J Leistung:
-16.08%
Sage Therapeutics Inc Stock (SAGE) Company Profile
Firmenname
Sage Therapeutics Inc
Sektor
Branche
Telefon
617-299-8380
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie SAGE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SAGE
Sage Therapeutics Inc
|
9.08 | 437.72M | 91.06M | -503.14M | -424.74M | -8.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-11 | Fortgesetzt | BofA Securities | Underperform |
2024-11-21 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
2024-10-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2024-07-30 | Herabstufung | TD Cowen | Buy → Hold |
2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-05-29 | Eingeleitet | Citigroup | Sell |
2024-05-29 | Eingeleitet | Robert W. Baird | Neutral |
2024-04-17 | Herabstufung | BofA Securities | Neutral → Underperform |
2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
2023-08-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
2023-08-08 | Herabstufung | Goldman | Buy → Neutral |
2023-08-08 | Herabstufung | Needham | Buy → Hold |
2023-08-07 | Herabstufung | BofA Securities | Buy → Neutral |
2023-08-07 | Herabstufung | Oppenheimer | Outperform → Perform |
2023-08-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-08-07 | Herabstufung | Stifel | Buy → Hold |
2023-08-07 | Herabstufung | Wedbush | Outperform → Neutral |
2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
2023-03-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
2022-11-01 | Eingeleitet | Loop Capital | Hold |
2022-03-31 | Eingeleitet | Berenberg | Hold |
2021-11-02 | Hochstufung | Guggenheim | Neutral → Buy |
2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2021-10-07 | Herabstufung | Jefferies | Buy → Hold |
2021-09-23 | Eingeleitet | Needham | Buy |
2021-06-16 | Herabstufung | Citigroup | Buy → Neutral |
2021-04-07 | Eingeleitet | Piper Sandler | Overweight |
2021-02-26 | Herabstufung | Mizuho | Buy → Neutral |
2021-02-25 | Bestätigt | H.C. Wainwright | Neutral |
2021-02-02 | Fortgesetzt | Raymond James | Mkt Perform |
2021-01-22 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
2021-01-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2020-12-04 | Hochstufung | Mizuho | Neutral → Buy |
2020-12-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-11-06 | Bestätigt | H.C. Wainwright | Neutral |
2020-09-11 | Hochstufung | Wedbush | Neutral → Outperform |
2020-08-10 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2020-05-08 | Herabstufung | Wedbush | Outperform → Neutral |
2020-04-08 | Herabstufung | Guggenheim | Buy → Neutral |
2020-03-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2020-03-06 | Eingeleitet | Citigroup | Buy |
2020-02-28 | Bestätigt | H.C. Wainwright | Neutral |
2020-02-06 | Eingeleitet | Mizuho | Neutral |
2019-12-06 | Bestätigt | RBC Capital Mkts | Outperform |
2019-12-05 | Bestätigt | Guggenheim | Buy |
2019-12-05 | Herabstufung | SunTrust | Buy → Hold |
2019-10-30 | Eingeleitet | H.C. Wainwright | Neutral |
2019-05-23 | Eingeleitet | Wedbush | Outperform |
2019-04-25 | Eingeleitet | Jefferies | Buy |
2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
2018-10-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire
H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance
Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar
SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus
Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus
Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus
SAGE Stock Rating Maintained as Price Target is Raised by Canacc - GuruFocus
SAGE Price Target Raised Amid Acquisition News | SAGE Stock News - GuruFocus
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone - Benzinga
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com
Piper Sandler Downgrades Sage Therapeutics (SAGE) Following Acqu - GuruFocus
Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine
Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com
Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald
These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's
Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus
Supernus’ $795 million bid sufficient for Sage - The Pharma Letter
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics By Stocktwits - Investing.com India
Supernus enters depression drug market with up to $795 million Sage deal - Reuters
Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating - marketscreener.com
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga
Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks
Supernus to buy Sage for up to $795 million - Axios
Sage Therapeutics Stock Explodes Over 35% in Massive Rally on Nasdaq - Daily Chhattisgarh News
Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener
Supernus strikes deal to buy Sage Therapeutics - The Business Journals
After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum
SAGE Stock Rating Reiterated as Hold by Needham | SAGE Stock New - GuruFocus
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl
SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada
Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral - marketscreener.com
After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston
Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals
Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus
Finanzdaten der Sage Therapeutics Inc-Aktie (SAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):